{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:58:00Z","timestamp":1786679880220,"version":"build-2736575974"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1053\/j.semnuclmed.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:16:29Z","timestamp":1739218589000},"page":"240-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Current Status of Staging and Restaging Malignant Pleural Mesothelioma"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0001","first-page":"127","article-title":"Clinical staging of malignant pleural mesothelioma: Current perspectives","volume":"8","author":"Bonomi","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0002","series-title":"Diffuse Pleural Mesothelioma. WHO Classification of Tumors Editorial Board","author":"Sauter","year":"2021"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.01.003_bib0003","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1053\/j.semnuclmed.2022.07.005","article-title":"FDG PET\/CT for staging and restaging malignant mesothelioma","volume":"52","author":"Lopci","year":"2022","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.01.003_bib0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2022.11.018","article-title":"Considerations for imaging of malignant pleural Mesothelioma: A consensus statement from the International Mesothelioma Interest Group","volume":"18","author":"Katz","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0005","series-title":"Thoracic Tumours","year":"2020"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.01.003_bib0006","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.semnuclmed.2021.04.002","article-title":"PET\/CT variants and pitfalls in lung cancer and mesothelioma","volume":"51","author":"Lopci","year":"2021","journal-title":"Semin Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.01.003_bib0007","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3390\/diagnostics12122905","article-title":"New insights in pleural mesothelioma classification update: Diagnostic traps and prognostic implications","volume":"12","author":"Mastromarino","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.01.003_bib0008","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO classification of tumors of the pleura: Advances since the 2015 classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.01.003_bib0009","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.3390\/curroncol31090368","article-title":"Diagnosis of pleural mesothelioma: is everything solved at the present time?","volume":"31","author":"Roca","year":"2024","journal-title":"Curr Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0010","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M descriptors and for revision of the TNM Stage Groupings in the forthcoming (Eighth) edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0011","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: Proposals for re-visions of the N descriptors in the forthcoming eighth edition of the TNM Classification for pleural Mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.01.003_bib0012","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","volume":"11","author":"Nowak","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.01.003_bib0013","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","article-title":"ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.Org. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Popat","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0014","unstructured":"https:\/\/www.nccn.org\/login,?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/meso_pleural.pdf, 2020. Accessed November 27, 2024"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.01.003_bib0016","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.jtho.2024.01.018","volume":"19","author":"Wolf","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0017","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0018","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jtho.2024.05.002","article-title":"The International Association for the Study of Lung Cancer pleural mesothelioma staging project: Proposal for revision of the TNM stage groupings in the forthcoming (ninth) edition of the TNM classification for pleural mesothelioma","volume":"19","author":"Nowak","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0019","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00259-010-1704-x","article-title":"FDG PET\/CT patterns of treatment failure of malignant pleural mesothelioma: Relationship to histologic type, treatment algorithm, and survival","volume":"38","author":"Gerbaudo","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/thx.52.6.507","article-title":"Malignant mesothelioma in South East England: Clinicopathological expe-rience of 272 cases","volume":"52","author":"Yates","year":"1997","journal-title":"Thorax"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.01.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01254-2018","article-title":"Investigating unilateral pleural effusions: the role of cytology","volume":"52","author":"Arnold","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0022","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2214\/ajr.154.3.2106209","article-title":"CT in differential diagnosis of diffuse pleural disease","volume":"154","author":"Leung","year":"1990","journal-title":"Am J Roentgenol"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0023","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification-update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0024","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000503239","article-title":"Diagnostic value of computed tomography imaging features in malignant pleural mesothelioma","volume":"99","author":"Fortin","year":"2020","journal-title":"Respiration"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.lungcan.2016.11.010","article-title":"The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy","volume":"103","author":"Tsim","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0026","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.semtcvs.2009.06.005","article-title":"Pathologic evaluation of malignant pleural mesothelioma","volume":"21","author":"Chirieac","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0027","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1148\/rg.317115505","article-title":"Role of imaging in the diagnosis, staging, and treatment of thymoma","volume":"31","author":"Benveniste","year":"2011","journal-title":"Radiographics"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0028","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.rcl.2015.12.006","article-title":"Solitary fibrous tumors: 2016 imaging update","volume":"54","author":"Keraliya","year":"2016","journal-title":"Radiol Clin North Am"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0029","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1258\/ar.2010.100292","article-title":"Thoracic epithelioid hemangioendothelioma: Imaging and pathologic features","volume":"52","author":"Kim","year":"2011","journal-title":"Acta Radiol"},{"issue":"1-2","key":"10.1053\/j.semnuclmed.2025.01.003_bib0030","first-page":"43","article-title":"Diagnosi con Tomografia Computerizzata del mesotelioma pleurico maligno. Studio multicentrico [The computed tomographic diagnosis of malignant pleural mesothelioma. A multicenter study]","volume":"84","author":"Falaschi","year":"1992","journal-title":"Radiol Med"},{"issue":"17","key":"10.1053\/j.semnuclmed.2025.01.003_bib0031","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.3390\/cancers13174377","article-title":"New updates of the imaging role in diagnosis, staging, and response treatment of malignant pleural mesothelioma","volume":"13","author":"Romei","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"142","key":"10.1053\/j.semnuclmed.2025.01.003_bib0032","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1183\/16000617.0063-2016","article-title":"Malignant pleural mesothelioma: An update on investigation, diagnosis and treatment","volume":"25","author":"Bibby","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.01.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01295-2023","article-title":"PET-CT-guided versus CT-guided biopsy in suspected malignant pleural thickening: A randomised trial","volume":"63","author":"de Fonseka","year":"2024","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.01.003_bib0034","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2214\/ajr.172.4.10587144","article-title":"Staging of malignant pleural mesothelioma: Comparison of CT and MR imaging","volume":"172","author":"Heelan","year":"1999","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.01.003_bib0035","doi-asserted-by":"crossref","first-page":"750","DOI":"10.3390\/diagnostics12030750","article-title":"The use of chest magnetic resonance imaging in malignant pleural mesothelioma diagnosis","volume":"12","author":"Volpi","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0036","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","article-title":"Early contrast enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy","volume":"118","author":"Tsim","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0037","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/JTO.0b013e3181c0a7ff","article-title":"Clinical value of fluorodeoxyglucose-positron emission to-mography computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease","volume":"12","author":"Yildrim","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0038","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-2008-1039314","article-title":"The role of positron emission tomograohy \/computed tomography in the diagnosis of pleural diseases","volume":"57","author":"Orki","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0039","first-page":"333","article-title":"Clinical implications of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma","volume":"27","author":"Abe","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0040","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1378\/chest.114.3.713","article-title":"Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography","volume":"9","author":"Benard","year":"1998","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0041","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/RLU.0b013e31815c5004","article-title":"Systemic disseminated tuberculosis mimicking malignancy on F-18 FDG PET-CT","volume":"33","author":"Li","year":"2008","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0042","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/etm.2012.572","article-title":"Clinical utility of 18-fluorodeoxyglucose positron emission tomography\/computed tomography in malignant pleural mesothelioma","volume":"4","author":"Terada","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0043","first-page":"149","article-title":"Role of 18F-FDG PET for evaluating malignant pleural me-sothelioma","volume":"4","author":"Nanni","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0044","first-page":"111","article-title":"Additional value of hybrid PET\/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma","volume":"8","author":"Ambrosini","year":"2005","journal-title":"Nucl Med Rev"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0045","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejcts.2008.07.050","article-title":"Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy","volume":"34","author":"Sorensen","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0046","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3816\/CLC.2009.n.033","article-title":"Utility of integrated computed tomography positron emission tomography for selection of operable malignant pleural mesothelioma","volume":"10","author":"Wilcox","year":"2009","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0047","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.01.003_bib0048","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0049","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.01.003_bib0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0051","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0052","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.01.003_bib0053","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1053\/j.semnuclmed.2022.04.008","article-title":"A role for PET\/CT in response assessment of malignant pleural mesothelioma","volume":"52","author":"Sandach","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0054","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0055","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0056","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0057","doi-asserted-by":"crossref","unstructured":"Lopci E, Zucali PA: Malignant pleural mesothelioma: 18F-FDG PET\/CT for response assessment of malignant pleural mesothelioma following immunotherapy. In: Lopci E, Fanti S (eds): Atlas of Response to Immunotherapy, Cham: Springer, 2020","DOI":"10.1007\/978-3-030-31113-1"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0058","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.1182","article-title":"Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy","volume":"6","author":"Zucali","year":"2017","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0059","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0060","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0003-4975(96)01228-3","article-title":"Patterns of failure after trimodality therapy for malignant pleural mesothelioma","volume":"63","author":"Baldini","year":"1997","journal-title":"Ann Thorac Surg"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.01.003_bib0061","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thorsurg.2004.06.006","article-title":"Patterns of failure following surgical resection for malignant pleural mesothelioma","volume":"14","author":"J\u00e4nne","year":"2004","journal-title":"Thorac Surg Clin"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0062","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.ro.2013.03.017","article-title":"Malignant pleural mesothelioma: Role of CT, MRI, and PET\/CT in staging evaluation and treatment considerations","volume":"48","author":"Troung","year":"2013","journal-title":"Semin Roentgenol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0063","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.clinimag.2013.06.009","article-title":"18F-FDG PET\/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to stand-and diagnostic follow-up)","volume":"37","author":"Niccoli-Asabella","year":"2013","journal-title":"Clin Imaging"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0064","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11604-016-0555-1","article-title":"Present and future roles of FDGPET\/CT imaging in the management of malignant pleural mesothelioma","volume":"34","author":"Kitajima","year":"2016","journal-title":"Jpn J Radiol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.01.003_bib0065","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1136\/thoraxjnl-2021-217709","article-title":"Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: A population-based study","volume":"77","author":"van Kooten","year":"2022","journal-title":"Thorax"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0066","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11523-023-01017-w","article-title":"Malignant pleural mesothelioma: Staging and radiological response criteria in patients treated with immune checkpoint inhibitors","volume":"19","author":"Martella","year":"2024","journal-title":"Target Oncol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.01.003_bib0067","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.3390\/diagnostics12123009","article-title":"Diagnostic and therapeutic challenges of malignant pleural mesothelioma","volume":"12","author":"Moro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0068","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/bjc.2017.22","article-title":"Prognostication and monitoring of mesothelioma using biomarkers: A systematic review","volume":"116","author":"Arnold","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0069","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant mesothelioma biomarkers: From discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0070","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble Mesothelin concentrations in malignant pleural mesothelioma: Relationship to tumor volume, clinical stage, and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0071","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0072","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2014.02.024","article-title":"Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: A systematic review and meta-analysis","volume":"433","author":"Hu","year":"2014","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0073","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1471-2407-13-205","article-title":"Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma","volume":"13","author":"Tabata","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0074","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/bjc.2015.470","article-title":"A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma","volume":"114","author":"Kao","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0075","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0076","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/cas.13895","article-title":"Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma","volume":"110","author":"Yoneda","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102949","article-title":"Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review","volume":"150","author":"Ahmadzada","year":"2020","journal-title":"Crit Rev Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0078","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0079","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/bjc.2015.62","article-title":"The South West Area Mesothelioma and Pemetrexed trial: A multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication","volume":"112","author":"Hooper","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0080","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.3390\/jcm12227006","article-title":"Pleural mesothelioma: advances in blood and Pleural biomarkers","volume":"12","author":"Sorino","year":"2023","journal-title":"J Clin Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0081","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00919-2017","article-title":"Exhaled breath to screen for malignant pleural mesothelioma: A validation study","volume":"50","author":"Lamote","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0082","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/acf7e3","article-title":"Determining the clinical utility of a breath test for screening an asbes-tos-exposed population for pleural mesothelioma: baseline results","volume":"17","author":"Zwijsen","year":"2023","journal-title":"J Breath Res"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0083","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1056\/NEJMc071823","article-title":"11C-labeled methionine and evaluation of malignant pleural mesothelioma","volume":"357","author":"Ceresoli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0084","first-page":"4075","article-title":"L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma","volume":"31","author":"Kaira","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0085","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/MNM.0000000000001078","article-title":"In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma","volume":"40","author":"Lopci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0086","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","article-title":"68Ga-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma","volume":"47","author":"G\u00fcndo\u011fan","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0087","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MNM.0000000000001702","article-title":"Comparison of the role of 18F-fluorodeoxyglucose PET\/computed tomography and 68Ga-labeled FAP inhibitor-04 PET\/CT in patients with malignant mesothelioma","volume":"44","author":"G\u00fczel","year":"2023","journal-title":"Nucl Med Commun"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.01.003_bib0088","first-page":"e3654","article-title":"Fluorodeoxyglucose versus choline positron emission tomography\/computed tomography response evaluation in two malignant pleural mesothelioma patients treated with Talc Pleurodesis and Neoadjuvant Chemotherapy","volume":"10","author":"Kitajima","year":"2018","journal-title":"Cureus"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0089","article-title":"Role of 3\u2019-deoxy-3\u2019-[18F] fluorothymidine positron emission tomography-computed tomography as a predictive biomarker in argininosuccinate synthetase 1-deficient thoracic cancers treated with pegargiminase","volume":"3","author":"Szyszko","year":"2022","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.01.003_bib0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/1754-9485.13592","article-title":"The prognostic value of F18 fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy\u2014A prospective cohort study","volume":"68","author":"May","year":"2024","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0091","doi-asserted-by":"crossref","first-page":"96732","DOI":"10.18632\/oncotarget.18235","article-title":"Targeting CXCR4 with [68Ga]Pentixafor: A suitable theranostic approach in pleural mesothelioma?","volume":"8","author":"Lapa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0092","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/RLU.0000000000005123","article-title":"18F-FDG and 68Ga-PSMA PET\/CT in paratesticular mesothelioma","volume":"49","author":"Kalantari","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0093","first-page":"2015","article-title":"A novel PET imaging using \u2076\u2074cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells","volume":"268172","author":"Kobayashi","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0094","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1016\/j.bmcl.2017.05.077","article-title":"Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma","volume":"27","author":"Huang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.01.003_bib0095","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.jtho.2020.03.025","article-title":"Transitional mesothelioma and artificial intelligence: do we need one more subtype? And do we need computers to identify them?","volume":"15","author":"Carbone","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0096","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/comjnl\/bxab015","article-title":"A machine learning approach for identification of malignant mesothelioma etiological factors in an imbalanced dataset","volume":"65","author":"Alam","year":"2021","journal-title":"Comput. J."},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0097","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3233\/THC-202237","article-title":"Predicting cancer using supervised machine learning: Mesothelioma","volume":"29","author":"Choudhury","year":"2021","journal-title":"Technol Health Care"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0098","doi-asserted-by":"crossref","DOI":"10.1080\/08839514.2021.2018182","article-title":"A novel multi-neural ensemble approach for cancer diagnosis","volume":"36","author":"Gupta","year":"2022","journal-title":"Appl Artif Intell"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.01.003_bib0099","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/thoraxjnl-2021-217808","article-title":"Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: Validation and comparison with modified RECIST response criteria","volume":"77","author":"Kidd","year":"2022","journal-title":"Thorax"},{"key":"10.1053\/j.semnuclmed.2025.01.003_bib0100","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:41:18Z","timestamp":1741909278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0001299825000029"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.01.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Status of Staging and Restaging Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}